+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HER2-Positive Breast Cancer - Epidemiology Forecast to 2030

  • PDF Icon

    Report

  • 61 Pages
  • August 2021
  • Region: Global
  • GlobalData
  • ID: 5440001
Description Jump to:
Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent. Breast cancer is classified based on human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (American Cancer Society, 2019). HER2-/HR+ and HER2-/HR- were analyzed in the HER2-negative breast cancer report. This report explores HER2-positive breast cancer, namely, HER2+/HR+ and HER2+/HR- breast cancer.

The publisher epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HER2-positive breast cancer. The publisher epidemiologists applied country-specific incidence rates of HER2-positive breast cancer wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of HER2+/HR+ and HER2+/HR- cases. In 2020, the 8MM had 97,308 diagnosed incident cases of HER2/HR+ breast cancer. This is expected to increase to 113,608 diagnosed incident cases by 2030, at an Annual Growth Rate (AGR) of 1.68%. In the 8MM, the diagnosed incident cases of HER2+/HR- breast cancer will increase from 53,824 cases in 2020 to 63,106 cases in 2030, at an AGR of 1.72%. This increase is partly attributed to the moderately rising trend in historical incidence in the 8MM, combined with underlying demographic changes in the respective markets. The early diagnosis and development of more effective therapies would improve survival from HER2-positive breast cancer.

Scope


  • HER2-Positive Breast Cancer Epidemiology Report provides an overview of the risk factors and global trends of HER2-positive in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 8MM: diagnosed incident cases of all invasive, HER2+/HR+, and HER2+/HR- breast cancer; diagnosed five-year prevalent cases of HER2+/HR+, and HER2+/HR- breast cancer; and diagnosed incident cases of HER2+/HR+ and HER2+/HR- breast cancer by cancer staging. Additionally, diagnosed incident cases of HER2+HR+ and HER2+/HR- breast cancer cases are further segmented by metastasis, and biomarker expression. HER2+/HR+ and HER2+/HR- breast cancer cases are also segmented by menopausal status.
  • The HER2-Positive Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy


The HER2-Positive Breast Cancer Epidemiology series will allow you to:


  • Develop business strategies by understanding the trends shaping and driving the global HER2-positive breast cancer market.
  • Quantify patient populations in the global HER2-positive market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the HER2-positive cancer stages that present the best opportunities for HER2- positive therapeutics in each of the markets covered.
  • Understand magnitude of HER2-positive breast cancer market by biomarkers.

Table of Contents

1 HER2-Positive Breast Cancer: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 Forecast Methodology
2.4.1 Sources Used
2.4.2 Forecast Assumptions and Methods
2.5 Epidemiological Forecast for All Invasive and HER2-Positive Breast Cancer (2020-2030)
2.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer
2.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer
2.5.3 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer
2.5.4 Diagnosed Incident Cases of HER2+/HR- Breast Cancer
2.5.5 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stages
2.5.6 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stages
2.5.7 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status
2.5.8 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status
2.5.9 Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression
2.5.10 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression
2.5.11 Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression
2.5.12 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis
2.5.13 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis
2.5.14 Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression
2.5.15 Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 COVID-19 Impact
2.6.3 Limitations of Analysis
2.6.4 Strengths of Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
3.3 Contact the Publisher
List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for All Invasive HER2-Positive Breast Cancer
List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of HER2+/HR+ Breast Cancer, Women, N, Ages =18 Years, 2020 and 2030
Figure 2: 8MM, Diagnosed Incident Cases of HER2+/HR- Breast Cancer, Women, N, Ages =18 Years, 2020 and 2030
Figure 3 : 8MM, Diagnosed Incidence of HER2+/HR+ Breast Cancer, Ages =18 Years, Women, Cases per 100,000 Population, 2010?2030
Figure 4: 8MM, Diagnosed Incidence of HER2+/HR- Breast Cancer, Ages =18 Years, Women, Cases per 100,000 Population, 2010?2030
Figure 5: 8MM, Sources Used and Not Used for Diagnosed Incident Cases of All Invasive Breast Cancer
Figure 6: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer
Figure 7: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Stage
Figure 8: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Menopausal Status
Figure 9: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by PD-1 and PD-L1 Expression
Figure 10: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Ki67, NTRK, and RET Expression
Figure 11: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Bone and Brain Metastasis
Figure 12: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by IHC3+ Expression
Figure 13: 8MM, Sources Used for Five-Year Diagnosed Prevalent Cases of HER2+/HR+ and HER2+/HR- Breast Cancer
Figure 14: 8MM, Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages =18 Years, N, 2020
Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages =18 Years, N, 2020
Figure 16: 8MM, Diagnosed Incident Cases of HER2+/HR+ Breast Cancer, Women, Ages =18 Years, N, 2020
Figure 17: 8MM, Diagnosed Incident Cases of HER2+/HR- Breast Cancer, Women, Ages =18 Years, N, 2020
Figure 18: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stage, Women, Ages =18 Years, N, 2020
Figure 19: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stage, Women, Ages =18 Years, N, 2020
Figure 20: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status, Women, Ages =18 Years, %, 2020
Figure 21: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status, Women, Ages =18 Years, %, 2020
Figure 22: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression, Women, Ages =18 Years, N, 2020
Figure 23: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression, Women, Ages =18 Years, N, 2020
Figure 24: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression, Women, Ages =18 Years, N, 2020
Figure 25: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis, Women, Ages =18 Years, N, 2020
Figure 26: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis, Women, Ages =18 Years, N, 2020
Figure 27: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression, Women, Ages =18 Years, N, 2020
Figure 28: 8MM, Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer, Women, Ages =18 Years, N, 2020

Related Topics

Related Reports

Metastatic HER2 positive breast cancer - Pipeline Insight, 2024 - Product Image

Metastatic HER2 positive breast cancer - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Early Stage Hormone Receptor Positive & HER2Positive Breast Cancer (LATAM) - Pipeline Insight, 2024 - Product Image

Early Stage Hormone Receptor Positive & HER2Positive Breast Cancer (LATAM) - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
HER2 Inhibitors Global Market Report 2024 - Product Image

HER2 Inhibitors Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
HER2-Negative Breast Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

HER2-Negative Breast Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 200 Pages
  • Global
United States Breast Cancer Therapeutics Market, Competition, Forecast & Opportunities, 2028 - Product Image

United States Breast Cancer Therapeutics Market, Competition, Forecast & Opportunities, 2028

  • Report
  • 73 Pages
  • United States
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.